Gary Anthony Pestano
Chief Scientific OfficerDr. Gary Anthony Pestano, Ph.D., is Chief Scientific Officer of Biodesix, Inc. from 2026. Dr. Pestano had been Chief Development Officer at Biodesix, Inc. since October 2018 until 2026 and served as its Vice President of Product Development and Operations until October 2018. Dr. Pestano joined Biodesix in 2012 and held various roles related Product Development and Operations since March 2012. Dr. Pestano is a seasoned biotech leader and Heads up Product Development and Operations at Biodesix. Dr. Pestano has experience in laboratory and assay development for high complexity molecular diagnostics for oncology includes molecular and proteomic testing. Dr. Pestano led multidisciplinary teams in the development of tissue diagnostic tests, cancer vaccines and scientific software. He held senior positions in PharmaServices, R&D and Project Leadership at Ventana, a Member of the Roche Group from 2003 to 2012. Dr. Pestano is the co-inventor on multiple national and international patents for diagnostic tests. He also fostered many collaborations in academia and industry as a part of new product development. Dr. Pestano received a B.S. in Biochemistry from The City College of New York. Dr. Pestano received his Ph.D. training in Cell and Molecular biology at The Graduate Center, City University of New York and has Post-Doctoral Training in Cancer Immunology at the Dana Farber Cancer Institute, Harvard Medical School.
Positions
- Company NameBiodesix, Inc.Stock CodeBDSXPositionChief Scientific OfficerColleagues
- SHScott HuttonPresident, CEO & Director
- JPJohn PatienceIndependent Chairman
- RHRobin Harper CowieCFO, Secretary & Treasurer
- HRHeinrich RoderFounder & CTO
- JOJessica OlbrichtVice President of Human Resources
- MWMatthew W. StrobeckIndependent Director
- HMHany MassaranyIndependent Director
- JMJean M. FranchiIndependent Director
